




Webinar 7th November 2022

Strategies to mitigate the impact of COVID-19 on the Colorectal Cancer Screening Programme in the Basque Country (SPAIN)


PhD Isabel Portillo
Colorectal Cancer Screening Coordinator
Osakidetza-The Basque Health Service
Biocruces Health Research Institute
mariaisabel.portillovillares@osakidetza.eus





STRATEGIES TO MITIGATE COVID-19 PANDEMIC



PARTICIPATION RATE 2009-2021



COLONOSCOPIC SURVEILLANCE FOLLOWING INTERMEDIATE AND HIGH RISK ADENOMA



Copyright © 2010 v1 10/2010 W. Atkin et al.
The work may be copied provided this notice remains intact. No unauthorized revision or modification permitted.

36.2%

Advanced Lesions including serrated adenomas ≥3 years

1.5%

Advanced lesions ≥ 20mm sessil or flat piecemeal < 6 months

AEG and SEMFYC Guidelines 2018.
The Cancer Screening Spanish Network
<https://cribadocancer.es>



STEPS FORWARD

- Recover the delay in invitations in 2022 – 90% invited < 30 months
- Recover the participation rate in 2021 to prepandemic period including the following five waves (72.5% in 2018 to 72% 2021)
- Monitoring all CRC due to the delay in invitations ≠ Interval Cancer FIT
 - Interval Cancer FIT (monitored from 2009) - steady
 - Postcolonoscopy (non Interval Type B) – could increase middle-long term*
 - CRC because of delay in invitations (FIT > 30 months)*



THANK YOU VERY MUCH



The Basque CRC Screening (PCCR) team and research collaborators

www.osakidetza.euskadi.eus

mariaisabel.portillovillares@osakidetza.eus

